Objective:To explore the clinical efficacy of cognitive therapy combined with transcranial direct current stimulation in the treatment of schizophrenia.Methods:A randomized controlled study was conducted involving 118 patients with schizophrenia treated at The Second People's Hospital of Lishui from January 2021 to January 2023. The participants were divided into a control group and an observation group, with 59 patients in each group using a random number table method. The control group received cognitive therapy, while the observation group received cognitive therapy combined with transcranial direct current stimulation. Both groups underwent treatment for 8 weeks. Clinical symptom scores, treatment compliance, and the scores of Excited Component of the Positive and Negative Syndrome Scale, the Berkeley Expressivity Questionnaire, the Insight and Treatment Attitudes Questionnaire, and the Social Behavior Scale were compared between the two groups.Results:After intervention, the scores for activation, cognitive impairment, paranoia, depression, and aggression on the clinical symptom rating scale in the observation group were significantly lower than those in the control group ( t = 8.45, 6.68, 4.60, 6.92, 5.59, all P < 0.001). The overall compliance rate in the observation group was significantly higher than that in the control group [89.8% (53/59) vs. 74.6% (44/59), χ2 = 4.69, P < 0.05]. The score of Excited Component of the Positive and Negative Syndrome Scale in the observation group was significantly lower than that in the control group [(7.92 ± 1.75) vs. (9.35 ± 1.89), t = 4.26, P < 0.001]. The score of the Berkeley Expressivity Questionnaire in the observation group was significantly higher than that in the control group [(61.23 ± 5.79) vs. (55.38 ± 6.05), t = 5.37, P < 0.001]. The score of Insight and Treatment Attitudes Questionnaire in the observation group was significantly higher than that in the control group [(18.74 ± 3.69) vs. (12.41 ± 2.25), t = 11.25, P < 0.001]. The score of the Social Behavior Scale in the observation group was significantly lower than that in the control group [(15.23 ± 3.76) vs. (18.09 ± 4.28), t = 3.86, P < 0.001]. Conclusions:Cognitive therapy combined with transcranial direct current stimulation has shown significant effects in treating patients with schizophrenia. This combination therapy effectively improves treatment compliance and emotional expression abilities, alleviates symptoms of agitation, and enhances cognitive function and social skills in patients.

Objective:To explore the clinical efficacy of cognitive therapy combined with transcranial direct current stimulation in the treatment of schizophrenia.Methods:A randomized controlled study was conducted involving 118 patients with schizophrenia treated at The Second People's Hospital of Lishui from January 2021 to January 2023. The participants were divided into a control group and an observation group, with 59 patients in each group using a random number table method. The control group received cognitive therapy, while the observation group received cognitive therapy combined with transcranial direct current stimulation. Both groups underwent treatment for 8 weeks. Clinical symptom scores, treatment compliance, and the scores of Excited Component of the Positive and Negative Syndrome Scale, the Berkeley Expressivity Questionnaire, the Insight and Treatment Attitudes Questionnaire, and the Social Behavior Scale were compared between the two groups.Results:After intervention, the scores for activation, cognitive impairment, paranoia, depression, and aggression on the clinical symptom rating scale in the observation group were significantly lower than those in the control group ( t = 8.45, 6.68, 4.60, 6.92, 5.59, all P < 0.001). The overall compliance rate in the observation group was significantly higher than that in the control group [89.8% (53/59) vs. 74.6% (44/59), χ2 = 4.69, P < 0.05]. The score of Excited Component of the Positive and Negative Syndrome Scale in the observation group was significantly lower than that in the control group [(7.92 ± 1.75) vs. (9.35 ± 1.89), t = 4.26, P < 0.001]. The score of the Berkeley Expressivity Questionnaire in the observation group was significantly higher than that in the control group [(61.23 ± 5.79) vs. (55.38 ± 6.05), t = 5.37, P < 0.001]. The score of Insight and Treatment Attitudes Questionnaire in the observation group was significantly higher than that in the control group [(18.74 ± 3.69) vs. (12.41 ± 2.25), t = 11.25, P < 0.001]. The score of the Social Behavior Scale in the observation group was significantly lower than that in the control group [(15.23 ± 3.76) vs. (18.09 ± 4.28), t = 3.86, P < 0.001]. Conclusions:Cognitive therapy combined with transcranial direct current stimulation has shown significant effects in treating patients with schizophrenia. This combination therapy effectively improves treatment compliance and emotional expression abilities, alleviates symptoms of agitation, and enhances cognitive function and social skills in patients.

Background and purpose:Intracellular deubiquitylating enzymes,such as ubiquitin-specific peptidase 2(USP2),play a pivotal role in regulating protein degradation and cellular homeostasis by modulating protein ubiquitin deconjugation,which have been implicated in the proliferation and survival of multiple myeloma(MM)cells.Targeting the inhibition of USP2 activity in MM cells might modulate their biological behavior.This study aimed to investigate regulatory effects of the leukotriene receptor antagonist montelukast sodium on USP2 in MM cells and its subsequent biological effects.Methods:An in vitro deubiquitination reaction system was established using purified USP2 protein and its substrate,the glutathione S-transferase(GST)tagged ubiquitin A-52 residue ribosomal protein fusion product(UbA52),known as GST-UbA52 protein.This system was used to characterize inhibitory effects of montelukast sodium on USP2 deubiquitinase activity.The MM cell lines MM1.S and H929 were used as in vitro models.Cellular thermal shift assay(CETSA)was subsequently employed to test interaction mode between montelukast sodium and USP2 in MM cells.Western blot assay was applied to detect expression levels of USP2 and its targeting regulators,including cell cycle supervisors cyclin D1(CCND1)and cyclin A1(CCNA1),classical signaling transducer KRAS and glucose regulated protein 78kD(GRP78),as well as apoptotic molecule C/EBP-homologous protein(CHOP)in MM1.S and H929 cells before and after the treatment with different concentrations of montelukast sodium.MM cells with either overexpression(H929-OE,MM1.S-OE)or knockdown(H929-LE,MM1.S-LE)of USP2 were generated using a lentiviral vector.Cell counting kit-8(CCK-8)and flow cytometry were utilized to detect the proliferation and apoptotic rates of H929-OE,MM1.S-OE,H929-LE and MM1.S-LE cells treated with montelukast sodium.Results:Montelukast sodium was found to inhibit USP2 mediated degradation of GST-UbA52 protein in a concentration-dependent manner,with a half inhibitory concentration(IC50)of 3.814 μmol/L.Additionally,montelukast sodium significantly enhanced the thermal stability of USP2 at temperatures of 49.1,53.2 and 56.4℃.It was also shown that montelukast sodium could down-regulate expressions of CCND1,CCNA1 and KRAS,while increase levels of GRP78 and CHOP in MM1.S and H929 cells.Furthermore,after treating with 40 μmol/L montelukast sodium for 24 h,the proliferation inhibition and apoptotic rate of H929-OE cells reached to(37.68±1.10)%and(18.99±0.26)%,while the proliferation inhibition and apoptotic rate of MM1.S-OE cells reached to(24.48±0.49)%and(33.29±0.75)%,which were significantly lower than those in H929 and MM1.S cells[H929:(57.19±1.93)%and(45.65±0.24)%;MM1.S:(50.04±0.53)%and(40.25±0.91)%;P＜0.05,n=3].Conversely,the proliferation inhibition and apoptotic rates of H929-LE and MM1.S-LE cells were significantly higher[H929-LE-1#:(80.70±1.60)%and(89.08±0.49)%;H929-LE-2#:(75.30±3.80)%and(82.41±1.07)%;MM1.S-LE-1#:(70.64±0.84)%and(67.63±0.21)%;MM1.S-LE-2#:(68.47±1.32)%and(85.90±0.18)%;P＜0.05,n=3].Conclusion:Montelukast sodium can target ubiquitin proteasome regulator USP2 and inhibit its deubiquitylating activity,which may modulate USP2 directing protein and trigger endoplasmic reticulum stress to induce cell cycle arrest and apoptosis in MM cells.

Background and purpose:Intracellular deubiquitylating enzymes,such as ubiquitin-specific peptidase 2(USP2),play a pivotal role in regulating protein degradation and cellular homeostasis by modulating protein ubiquitin deconjugation,which have been implicated in the proliferation and survival of multiple myeloma(MM)cells.Targeting the inhibition of USP2 activity in MM cells might modulate their biological behavior.This study aimed to investigate regulatory effects of the leukotriene receptor antagonist montelukast sodium on USP2 in MM cells and its subsequent biological effects.Methods:An in vitro deubiquitination reaction system was established using purified USP2 protein and its substrate,the glutathione S-transferase(GST)tagged ubiquitin A-52 residue ribosomal protein fusion product(UbA52),known as GST-UbA52 protein.This system was used to characterize inhibitory effects of montelukast sodium on USP2 deubiquitinase activity.The MM cell lines MM1.S and H929 were used as in vitro models.Cellular thermal shift assay(CETSA)was subsequently employed to test interaction mode between montelukast sodium and USP2 in MM cells.Western blot assay was applied to detect expression levels of USP2 and its targeting regulators,including cell cycle supervisors cyclin D1(CCND1)and cyclin A1(CCNA1),classical signaling transducer KRAS and glucose regulated protein 78kD(GRP78),as well as apoptotic molecule C/EBP-homologous protein(CHOP)in MM1.S and H929 cells before and after the treatment with different concentrations of montelukast sodium.MM cells with either overexpression(H929-OE,MM1.S-OE)or knockdown(H929-LE,MM1.S-LE)of USP2 were generated using a lentiviral vector.Cell counting kit-8(CCK-8)and flow cytometry were utilized to detect the proliferation and apoptotic rates of H929-OE,MM1.S-OE,H929-LE and MM1.S-LE cells treated with montelukast sodium.Results:Montelukast sodium was found to inhibit USP2 mediated degradation of GST-UbA52 protein in a concentration-dependent manner,with a half inhibitory concentration(IC50)of 3.814 μmol/L.Additionally,montelukast sodium significantly enhanced the thermal stability of USP2 at temperatures of 49.1,53.2 and 56.4℃.It was also shown that montelukast sodium could down-regulate expressions of CCND1,CCNA1 and KRAS,while increase levels of GRP78 and CHOP in MM1.S and H929 cells.Furthermore,after treating with 40 μmol/L montelukast sodium for 24 h,the proliferation inhibition and apoptotic rate of H929-OE cells reached to(37.68±1.10)%and(18.99±0.26)%,while the proliferation inhibition and apoptotic rate of MM1.S-OE cells reached to(24.48±0.49)%and(33.29±0.75)%,which were significantly lower than those in H929 and MM1.S cells[H929:(57.19±1.93)%and(45.65±0.24)%;MM1.S:(50.04±0.53)%and(40.25±0.91)%;P＜0.05,n=3].Conversely,the proliferation inhibition and apoptotic rates of H929-LE and MM1.S-LE cells were significantly higher[H929-LE-1#:(80.70±1.60)%and(89.08±0.49)%;H929-LE-2#:(75.30±3.80)%and(82.41±1.07)%;MM1.S-LE-1#:(70.64±0.84)%and(67.63±0.21)%;MM1.S-LE-2#:(68.47±1.32)%and(85.90±0.18)%;P＜0.05,n=3].Conclusion:Montelukast sodium can target ubiquitin proteasome regulator USP2 and inhibit its deubiquitylating activity,which may modulate USP2 directing protein and trigger endoplasmic reticulum stress to induce cell cycle arrest and apoptosis in MM cells.

Objective:To investigate the effect and related mechanism of quetiapine fumarate tablets combined with valproate sodium tablets in the treatment of depression, and its influence on quality of life.Methods:From January 2017 to January 2019, 96 patients with depression admitted to the Second People's Hospital of Lishui were divided into control group ( n=48) and observation group ( n=48) according to the random digital table method.The patients in the observation group were treated with quetiapine fumarate tablets combined with sodium valproate tablets, while the patients in the control group were treated with sodium valproate.Both two groups were treated for 8 weeks.The therapeutic efficacy, Pittsburgh Sleep Quality Index (PSQI), Hamilton Depression Scale (HAMD), 5-HT, substance P (SP), neuropeptide Y (NPY) and World Health Organization Quality of Life Scale (WHOQOL-BREEF) were compared before and after treatment. Results:The total effective rate of the observation group (91.67%) was higher than that of the control group (70.83%) (χ 2=6.838, P<0.05). After treatment, the scores of PSQI and HAMD in the observation group[(8.74±1.29)points and (14.35±1.37)points] were lower than those in the control group [(10.85±1.43)points and (21.19±2.09)points] ( t=7.591, 18.963, all P<0.05). After treatment, the serum levels of 5-HT [(43.17±7.46)μg/L] and NPY [(7.98±0.43)mg/L] in the observation group were higher than those in the control group [(34.36±5.18)μg/L and (6.59±0.37)mg/L], while the SP level [(3.98±0.54)mg/L] in the observation group was lower than that in the control group [(5.43±0.67)mg/L], the differences were statistically significant( t=6.721, 16.976, 11.674, all P<0.05). After treatment, the scores of environmental field [(65.78±2.63)points], social relationship[(60.31±3.25)points], psychology[(71.83±3.15)points] and physiology [(69.83±3.56)points] in the observation group were higher than those in the control group [(58.91±2.35)points, (54.73±2.32)points, (64.36±2.78)points, (61.15±2.89)points]( t=13.495, 9.682, 12.319, 13.115, all P<0.05). There was no statistically significant difference in adverse reactions between the two groups ( P>0.05). Conclusion:Quetiapine fumarate tablets combined with sodium valproate tablets is effective in the treatment of depression, which can increase serum 5-HT and NPY levels and decrease SP level, and improve the quality of life of patients.

ObjectiveTo explore the clinical effect of transcatheter hepatic arterial chemoembolization and systemic chemotherapy on colorectal cancer with hepatic metastasis.Methods50 cases of colon cancer with hepatic metastasis according to treatment methods were divided into A,B group.A group treated by TACE plus intravenous chemotherapy,B group treated by intravenous chemotherapy alone.Side effects,changes in liver tumor size and survival rate were observed.ResultsThe incidence of side effects of two groups had no significant difference ( P ＞ 0.05 ).A group of liver lesions smaller in size or stable is more than in group B( P ＜0.05 ).A group of 1 year,3 years survival rate is 84％and 64％respectively,which is higher than B group 56％and 36％ ( all P ＜ 0.05 ).ConclusionTranscatheter hepatic arterial chemoembolization and systemic chemotherapy is a safe and effective treatment of colon cancer with hepatic metastasis,it can obviously raise the survival rate.

Objective To analyze the effect and safety of interventional therapy by trans uterine artery for treatment of tubal pregnancy. Methods Forty-two patients with tubal pregnancy were performed two side uterine arteries. MTX perfusion and embolization with gelfoam particles guided by DSA fluoroscopy. Results Forty patients obtained the decline of serum β-HCG value and 39 patients' ectopic mass absorption after treatment. Two patients occurred ectopic mass bleeding after interventional therapy and emergency surgical operation were done, but the amount of bleeding was low than 400ml. Conclusion Interventional therapy by trans uterine artery for treatment of tubal pregnancy could preserve the function of fallopian tubal, it was more benefit for patients who want normal pregnancy.

R prognosticate the lesion of coronary artery in KD has influence on left ventricular function.

Brain Neoplasms ; Germinoma ; Humans ; Pineal Gland